Screener
Tectonic Therapeutics TECX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Tectonic Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212016
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $20,871 | $13,036 |
| General and administrative | 6,430 | 5,262 |
| Total operating expenses | 27,301 | 18,298 |
| Loss from operations | (27,301) | (18,298) |
| Other income (expense): | ||
| Interest income | 2,181 | 2,444 |
| Interest expense | (8) | (20) |
| Other expense | (113) | (32) |
Item 1. Financial Statements.
FAQ
- What is Tectonic Therapeutics's operating income?
- Tectonic Therapeutics (TECX) reported operating income of -$27.3M in Q1 2026.
- How has Tectonic Therapeutics's operating income changed year-over-year?
- Tectonic Therapeutics's operating income decreased by 49.2% year-over-year, from -$18.3M to -$27.3M.
- What is the long-term trend for Tectonic Therapeutics's operating income?
- Over 4 years (2021 to 2025), Tectonic Therapeutics's operating income has grown at a -8.3% compound annual growth rate (CAGR), from -$118.84M to -$84.04M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Tectonic Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude